CSL Biotherapies - Latest News [Page 1]

New study supports benefit of GARDASIL for males

Thursday, 27 October 2011, 4:08 pm | CSL Biotherapies

Results of a US study, published today in the New England Journal of Medicine (NEJM), support the growing body of evidence that GARDASIL® helps prevents not just females, but also males from developing certain human papillomavirus (HPV) related pre-cancers, ... More >>

Results support evidence that vaccine is effective

Tuesday, 19 May 2009, 9:18 am | CSL Biotherapies

New results from an extended follow-up study further support the evidence that GARDASIL®, the four-type (6, 11,  16, 18) human papillomavirus (HPV) vaccine, offers women long-term protection against developing pre-cancerous abnormalities or cervical cancer. More >>

Expansion of Govt cervical cancer vaccine programm

Friday, 23 January 2009, 12:11 pm | CSL Biotherapies

In February 2009 the HPV Immunisation Programme will be extended to include girls aged 12 – 18 years and will mostly be given via a school based programme. More >>

Cervical Cancer vaccine wins pharma “Nobel Prize”

Monday, 24 November 2008, 10:22 am | CSL Biotherapies

GARDASIL®, the vaccine used in the New Zealand cervical cancer immunisation programme, has won the prestigious 2008 International Galien Prize, according to Mike Taylor, New Zealand Country Manager for CSL Biotherapies NZ Ltd. More >>

180 women a day immunising against cervical cancer

Wednesday, 22 October 2008, 10:28 am | CSL Biotherapies

One month on from the start of the free National HPV Immunisation Programme and already 180 eligible women born in 1990 & 1991 are taking up immunisation each day, according to figures released by CSL Biotherapies, the biopharmaceutical company working with ... More >>

Appeal to PM on Cervical Cancer Vaccination

Wednesday, 23 May 2007, 9:55 am | CSL Biotherapies

CSL Biotherapies (NZ) Ltd is seeking an urgent meeting with the Prime Minister, Helen Clark, to discuss how the cervical cancer vaccine, Gardasil, can be funded in the 2008 immunisation schedule. Dave Bowler, General Manager of CSL Biotherapies (NZ) ... More >>